Vancolife Use In Pregnancy & Lactation

Reproduction studies in rats and rabbits at doses up to 5 and 3 times the maximum recommended human dose (MRHD), respectively, have revealed no teratogenic effects.
In a controlled clinical study, the potential ototoxic and nephrotoxic effects of this medicine on infants were evaluated when the drug was administered to pregnant women for serious staphylococcal infections complicating intravenous drug abuse. This medicine was found in cord blood. No sensorineural hearing loss or nephrotoxicity attributable to this medicine was noted.
One infant whose mother received this medicine in the third trimester experienced conductive hearing loss that was not attributed to the administration of this medicine. Because the number of patients treated in this study was limited and this medicine was administered only in the second and third trimesters, it is not known whether this medicine causes fatal harm.
The women who are pregnant or considering pregnancy should be administered only if the therapeutic benefits justify the potential risks. If needed, administration requires careful monitoring of blood concentration for reducing the risk of fetal toxicity.
Avoid using vancomycin to nursing mother because vancomycin is excreted in human milk. However, if inevitable, discontinue nursing.